Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Jonathan I Silverberg; Jacob P Thyssen; Eric L Simpson; Gil Yosipovitch; Sonja Ständer; Hernan Valdez; Ricardo Rojo; Pinaki Biswas; Daniela E Myers; Claire Feeney; Marco DiBonaventura

doi:10.1007/s40257-021-00634-3

Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Jonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, Gil Yosipovitch, Sonja Ständer, Hernan Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E Myers, Claire Feeney, Marco DiBonaventura

Dermatology, Department of

Abstract

Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) ^a and b Children’s Dermatology Life Quality Index (CDLQI) ^b band descriptors. ^aFor patients ≥ 8 years of age. ^bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) ^a and b Children’s Dermatology Life Quality Index (CDLQI) ^b band descriptors. ^aFor patients ≥ 18 years of age. ^bFor patients < 18 years of age.

Original language	English
Publication date	Sept 2021
Edition	5
Volume	22
Number of pages	1
DOIs	https://doi.org/10.1007/s40257-021-00634-3
Publication status	Published - Sept 2021

Series	American Journal of Clinical Dermatology
ISSN	1175-0561

Access to Document

10.1007/s40257-021-00634-3

Fingerprint

Dive into the research topics of 'Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes'. Together they form a unique fingerprint.

Cite this

Silverberg, J. I., Thyssen, J. P., Simpson, E. L., Yosipovitch, G., Ständer, S., Valdez, H., Rojo, R., Biswas, P., Myers, D. E., Feeney, C., & DiBonaventura, M. (2021, Sept). Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes. (5 ed.) American Journal of Clinical Dermatology https://doi.org/10.1007/s40257-021-00634-3

Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes. / Silverberg, Jonathan I; Thyssen, Jacob P; Simpson, Eric L et al.
1 p. 5 ed. 2021. (American Journal of Clinical Dermatology).

Research output: Other contribution › Research

Silverberg, JI, Thyssen, JP, Simpson, EL, Yosipovitch, G, Ständer, S, Valdez, H, Rojo, R, Biswas, P, Myers, DE, Feeney, C & DiBonaventura, M 2021, Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.. https://doi.org/10.1007/s40257-021-00634-3

@misc{8622d07e74b34e7e98c6a3579e9527a2,

title = "Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes",

abstract = "Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children{\textquoteright}s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children{\textquoteright}s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age. ",

author = "Silverberg, {Jonathan I} and Thyssen, {Jacob P} and Simpson, {Eric L} and Gil Yosipovitch and Sonja St{\"a}nder and Hernan Valdez and Ricardo Rojo and Pinaki Biswas and Myers, {Daniela E} and Claire Feeney and Marco DiBonaventura",

year = "2021",

month = sep,

doi = "10.1007/s40257-021-00634-3",

language = "English",

volume = "22",

series = "American Journal of Clinical Dermatology",

publisher = "Adis International Ltd",

edition = "5",

type = "Other",

}

TY - GEN

T1 - Correction to

T2 - Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

AU - Silverberg, Jonathan I

AU - Thyssen, Jacob P

AU - Simpson, Eric L

AU - Yosipovitch, Gil

AU - Ständer, Sonja

AU - Valdez, Hernan

AU - Rojo, Ricardo

AU - Biswas, Pinaki

AU - Myers, Daniela E

AU - Feeney, Claire

AU - DiBonaventura, Marco

PY - 2021/9

Y1 - 2021/9

N2 - Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children’s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children’s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age.

AB - Page 550, Fig. 4: The legend, which previously read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children’s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 8 years of age. bFor patients < 18 years of age. Should read: Fig. 4. Impact of treatment on a Dermatology Life Quality Index (DLQI) a and b Children’s Dermatology Life Quality Index (CDLQI) b band descriptors. aFor patients ≥ 18 years of age. bFor patients < 18 years of age.

UR - http://www.scopus.com/inward/record.url?scp=85112825822&partnerID=8YFLogxK

U2 - 10.1007/s40257-021-00634-3

DO - 10.1007/s40257-021-00634-3

M3 - Other contribution

C2 - 34406620

VL - 22

T3 - American Journal of Clinical Dermatology

ER -

Correction to: Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this